Imimate Cream

Actinic Keratosis (AK) is a growing global health concern caused by long-term UV exposure and can progress to squamous cell carcinoma if left untreated. Current treatments are often costly and may cause side effects, highlighting the need for safer, more accessible options. Investigating Clinacanthus nutans, a traditionally used medicinal plant, through modern scientific methods may offer an affordable and effective alternative for AK management.

Imimate Cream is formulated to alleviate Actinic Keratosis and contains a standardised Clinacanthus nutans extract enriched with chlorophyll. Designed to minimise discomfort while delivering targeted therapeutic action, Imimate reduces skin roughness, redness, scaling, and thickening without the harsh side effects seen in conventional therapies. Its gentle profile supports better patient compliance, making it suitable for sensitive and chronic-care users.

Imimate Cream works through photodynamic therapy (PDT), using a chlorophyll catabolite from Clinacanthus nutans. When applied to the skin and exposed to specific light (660 nm) or natural daylight, the active compound is activated and generates reactive oxygen species (ROS). These ROS selectively damage and destroy abnormal or precancerous skin cells by targeting their DNA, mitochondria, and membranes, leading to cell death.

PHASE I CLINICAL TRIAL RESULTS
Safety & Tolerability Evaluation

Study Design
1. Conducted at Hospital Al-Sultan Abdullah (HASA), UiTM
2. 92 healthy volunteers
3. Assessment of irritation, sensitisation, photoallergy, phototoxicity, and tolerability

Key Findings
1. No photoallergy reactions observed
2. No phototoxic reactions observed
3. Excellent overall skin tolerability

Conclusion Imimate demonstrates a favorable safety profile and was well tolerated for topical application

PHASE II CLINICAL TRIAL RESULTS
Actinic Keratosis Patients

Study Population
1. 23 patients with Actinic Keratosis

Key Findings
1. Clinically improvement in AK lesions
2. Reduces skin scaliness, thickness and inflammation
3. Comparable clinical outcomes to Imiquimod 5% cream with favorable tolerability

Conclusion Imimate demonstrates promising efficacy and strong safety profile in AK patients

INTERNATIONAL RECOGNITION
WHO Health & Heritage Innovation (H2I)
Awarded as one of the Top 21 Finalists worldwide under the WHO Health & Heritage Innovation (H2I) initiative.